A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107811
Title:
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.
Authors:
Lind, Michael J; Gomm, S; Simmonds, A P; Ashcroft, Linda; Kamthan, A; Gurney, H; Thatcher, Nick
Abstract:
A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. 1991, 28 (2):142-4 Cancer Chemother Pharmacol
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1991
URI:
http://hdl.handle.net/10541/107811
DOI:
10.1007/BF00689705
PubMed ID:
1647893
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLind, Michael Jen
dc.contributor.authorGomm, Sen
dc.contributor.authorSimmonds, A Pen
dc.contributor.authorAshcroft, Lindaen
dc.contributor.authorKamthan, Aen
dc.contributor.authorGurney, Hen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-16T15:55:18Z-
dc.date.available2010-07-16T15:55:18Z-
dc.date.issued1991-
dc.identifier.citationA phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. 1991, 28 (2):142-4 Cancer Chemother Pharmacolen
dc.identifier.issn0344-5704-
dc.identifier.pmid1647893-
dc.identifier.doi10.1007/BF00689705-
dc.identifier.urihttp://hdl.handle.net/10541/107811-
dc.description.abstractA total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshInterferon Alfa-2b-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.titleA phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.